Indications
Rystiggo is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
Composition
- Active substance
- rozanolixizumab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Rystiggo
- Active substance
- rozanolixizumab
- ATC code
- L04AL02
- Therapeutic area
- Myasthenia Gravis
- Marketing authorisation holder
- UCB Pharma
- Status
- Authorised